Safety Data and Beneficial Effects of the Combined Oral Contraceptive Ethinylestradiol 0.03 mg/Chlormadinone Acetate 2 mg (Belara®): A 13-Cycle, Observational Study in Routine Clinical Practice

By Pushparajah Daphnee S.  

Clinical Drug Investigation, Vol. 31, Iss. 2, 2011-02 ,pp. : 121-134

Adis International

Access to resources Recommend Favorite

Six-Month Evaluation of the Benefits of the Low-Dose Combined Oral Contraceptive Chlormadinone Acetate 2 mg/Ethinylestradiol 0.03 mg in Young Women: Results of the Prospective, Observational, Non-Interventional, Multicentre TeeNIS Study

By Anthuber Sabine  

Clinical Drug Investigation, Vol. 30, Iss. 4, 2010-04 ,pp. : 211-220

Adis International

Access to resources Recommend Favorite

Extended Cycles with the Combined Oral Contraceptive Chlormadinone Acetate 2 mg/Ethinylestradiol 0.03 mg: Pooled Analysis of Data from Three Large-Scale, Non-Interventional, Observational Studies

By Göretzlehner Gunther  

Clinical Drug Investigation, Vol. 31, Iss. 4, 2011-04 ,pp. : 269-277

Adis International

Access to resources Recommend Favorite

Efficacy and Tolerability of Moxifloxacin in Patients with Respiratory Tract Infections Treated in General Practice: Results of a Post-Marketing Surveillance Study

By Chen Weiqiang   Wu Changgui   Li Zhikui   Bai Changqing  

Clinical Drug Investigation, Vol. 26, Iss. 9, 2006-01 ,pp. : 501-509

Adis International

Access to resources Recommend Favorite

Efficacy and Tolerability of Moxifloxacin in Patients with Sinusitis Treated in General Practice: Results of a Post-Marketing Surveillance Study

By W. Elies  

Clinical Drug Investigation, Vol. 24, Iss. 8, 2004-01 ,pp. : 431-439

Adis International

Access to resources Recommend Favorite